GS1 US Releases New Framework for Pharmaceutical Saleable Returns

The guidance targets manufacturers, wholesalers, and healthcare providers, offering a structured approach to reconciling serialized identifiers with transaction data. By standardizing practices for return authorization and exception management, the resource seeks to eliminate the operational hurdles that occur when physical stock and digital records fail to align. Tracy Nasarenko, vice president of community engagement at GS1 US, noted that this consistency is vital for partners to make return decisions with greater speed and accuracy.

Under current DSCSA mandates, any prescription drug intended for resale requires rigorous verification of its product identifier alongside its associated Transaction Information and Transaction Statement. The new documentation integrates GS1 Standards—including Global Trade Item Numbers and Electronic Product Code Information Services—to ensure that data exchange remains reliable throughout the supply chain. This approach provides a clear path for resolving discrepancies when physical goods and accompanying digital documentation do not match, ultimately supporting the industry-wide goal of maintaining a secure and transparent pharmaceutical distribution network.